integrated analyses of the ovarian cancer genome cdk1 inhibition sensitises and tumours with wild...
DESCRIPTION
Ovarian CancerTRANSCRIPT
STANISLAV ALVARO CARDONAMEDICINE STUDENT
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME
CDK1 INHIBITION SENSITISES AND TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION
FOLDING
FOLDING
The ovarian cancer is one of the most
common in women. Some molecular
particles are important to stop it.
Inhibitors of the enzyme poly (ADP-ribose polymerase),
or PARP, in a study to stop the
development of some tumours
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME
July 4th 2011
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME
Ovarian cancer is a malignant tumor that arises in any part of the ovary due to mutation and cell
proliferation influenced by genetic, environmental or hereditary factors.
Its prognosis is good, on the rare occasions when diagnosed early
Ovarian cancer is the fifth most common cancer in women in the UK,
all over the world, representing approximately 4% of all cancers
diagnosed in women
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME
There are several genes involved in the development of this pathology as
BRCA1 BRCA2
RB1NF1
FAT3CSMD3
GABRA6CDK12
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME
This was determined by a genome study of women with ovarian cancer
which showed mutations in the mRNA during protein synthesis
I think that this is an important
step in the science, because
this would be the beginning of the treatment of
many pathologies
Understanding the genetic
material allows find the
answers for many medical
riddles
OBSERVATION
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION
July 4th 2011
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION
Inhibitors of the enzyme poly (ADP-ribose) polymerase, or PARP, are among the most
promising drugs currently in development as anti-tumour agents.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION
BRCA1 "breast cancer 1"BRCA1 "breast cancer 1" is a tumor suppressor gene, which regulate the cell cycle and prevent
uncontrolled proliferation.
CDK1CDK1is a highly conserved protein that
functions as a serine / threonine kinase, is encoded by the gene cdc2.
Phosphorylation of these proteins control cell cycle progression
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION
A combination of a PARP inhibitor with a Cdk1 inhibitor also showed
reduced tumour growth and prolonged survival compared to treatment with one or no inhibitors in a mouse model
of lung adenocarcinoma.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION
Inhibition of Cdk1 is likely to sensitise tumours with wild type BRCA1 to PARP inhibition, and that a combination of inhibitors of these two
enzymes may be a useful treatment for these tumours
That experiments are fundamental to
know how the human life is
affected begging in the littlest process
that define the whole life
OBSERVATION
MEDICAL UTILITY
MEDICAL UTILITY
The study of the human genome could shed any information about each
individual and that is where the solution begins each pathology
to develop it.
MEDICAL UTILITY
New experiments with enzymes have led to cures for various types of
cancer, starting with the molecular basis of such tumors which involve cell division and proper transfer of
genetic information.
Molecular biology is the basis for understanding the processes that lead to
cause such conditions, so find a solutions or improvements to the health of people
BIBLIOGRAPHY
• http://www.ecancermedicalscience.com/news-insider-news.asp?itemId=1857
• http://www.ecancermedicalscience.com/news-insider-news.asp?itemId=1858
• MARTINEZ SANCHEZ, LINA MARIA. , ET ALL. Biología Molecular, libro de clase. Sexta Edición. Universidad Pontificia Bolivariana. Medellín 2011
THANK YOU…